Key Players
Competitive Landscape
Key Players
Kenvue Inc. (Kimberly-Clark Corporation), Perrigo Company plc, Dr. Reddy's Laboratories Ltd., Cipla Health Ltd., Rusan Pharma Ltd. are covered in the competitive discussion.
Table 8: Company Developments and Commercial Implications
| Evidence | Commercial effect | Buyer action |
|---|---|---|
| Kimberly-Clark completes acquisition of Kenvue, 2 November 2026 | Nicorette gets a new parent with USD 2.1 billion of planned synergies across the combined group. | Pharmacy chains should review supply terms and promotions with the combined company. |
| Dr. Reddy's licenses Nicotinell to Hikma across the Middle East and North Africa, 28 September 2026 | Hikma gains exclusive rights to register, market and distribute Nicotinell in the region. | Distributors in the region should expect Nicotinell launches to follow local registration timelines. |
| India's Drugs Technical Advisory Board recommends limiting over-the-counter nicotine gum to unflavoured 2 mg, February 2026 | Open sale could narrow to unflavoured 2 mg gum, and 2 mg lozenges would need a sales licence. | Distributors in India should prepare for prescription or licensed-outlet requirements. |
How are the companies positioned?
Kenvue owns Nicorette and Haleon markets it in the United States. Dr. Reddy's holds Nicotinell outside the United States. Perrigo supplies store brands, while Cipla and Rusan Pharma sell nicotine gum in India.
What matters when a buyer qualifies a nicotine gum supplier?
Buyers confirm which company holds the brand rights in each country. Nicorette, for example, is licensed to a different marketer in the United States. Supply continuity terms also matter while Kimberly-Clark integrates Kenvue.
Which capabilities distinguish the product offers?
Brand rights, store brand supply and digital support separate the offers. Cipla pairs gum with a 12-week app, and Perrigo supplies store brand products.
How does geographic reach affect competition?
Dr. Reddy's holds Nicotinell and local brands such as Nicabate, Habitrol and Thrive outside the United States. Perrigo supplies store brand products.
Representative Company Overview
Table 9: Nicotine Gums and Mints Market Representative Company Overview
| Company | Positioning | Verified activity |
|---|---|---|
| Kenvue Inc. (Kimberly-Clark Corporation) | Owner of the Nicorette brand | Nicorette outperformed its category across major markets in the second quarter of 2026. Kimberly-Clark completed its acquisition of Kenvue on 2 November 2026. |
| Perrigo Company plc | Store brand over-the-counter and consumer self-care products supplier | Reported continued share gains of store brand nicotine replacement products in its third quarter 2026 results of 4 November 2026. |
| Dr. Reddy's Laboratories Ltd. | Indian pharmaceutical group and owner of Nicotinell outside the United States | Completed the purchase of Haleon's Nicotinell portfolio outside the United States on 30 September 2024 and licensed Nicotinell to Hikma for the Middle East and North Africa in September 2026. |
| Cipla Health Ltd. | Indian pharmaceutical group with the Nicotex brand | Launched the Nicotex Begin 12-week cessation app in May 2025. |
| Rusan Pharma Ltd. | Indian pharmaceutical company in nicotine replacement | Sells 2baconil nicotine gum in 2 mg and 4 mg strengths. |
Research Methodology
The nicotine gums and mints market assessment was conducted using primary interviews and secondary literature analysis combined with top-down data triangulation to validate market size, segment shares, and competitive positioning.
